{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:01:50Z","timestamp":1789722110699,"version":"4.0.1"},"reference-count":128,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14756366.2026.2717060","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:08:13Z","timestamp":1789718893000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Phthalazine as a medically versatile polyheterocyclic core with underexplored anticancer potential"],"prefix":"10.1080","volume":"41","author":[{"given":"Miko\u0142aj","family":"Biega\u0144ski","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Medical University of Warsaw","place":["Warsaw, Poland"]},{"name":"Department of Neurotoxicology, Mossakowski Medical Research Institute, Polish Academy of Sciences","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Matysiak","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Life Sciences in Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Szeliga","sequence":"additional","affiliation":[{"name":"Department of Neurotoxicology, Mossakowski Medical Research Institute, Polish Academy of Sciences","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"issue":"3","key":"e_1_3_3_2_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u2013263.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"e_1_3_3_3_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia Y","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin W-L. Drug repurposing for cancer therapy. Signal Transduct Target Ther. 2024;9(1):92.","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"e_1_3_3_4_1","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.3390\/molecules30214167","article-title":"Coumarin derivatives as anticancer agents: mechanistic landscape with an emphasis on breast cancer","volume":"30","author":"Hacholli VB","year":"2025","unstructured":"Hacholli VB, R SM, H PB, M L, S P, Kumar A, Szeleszczuk \u0141, Gackowski M. Coumarin derivatives as anticancer agents: mechanistic landscape with an emphasis on breast cancer. Molecules. 2025;30(21):4167.","journal-title":"Molecules"},{"issue":"12","key":"e_1_3_3_5_1","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2174\/1871520620666200424130204","article-title":"Synthesis, in vitro antitumor activity and molecular mechanism of novel furan derivatives and their precursors","volume":"20","author":"Lu D","year":"2020","unstructured":"Lu D, Zhou Y, Li Q, Luo J, Jiang Q, He B, Tang Q. Synthesis, in vitro antitumor activity and molecular mechanism of novel furan derivatives and their precursors. Anticancer Agents Med Chem. 2020;20(12):1475\u20131486.","journal-title":"Anticancer Agents Med Chem"},{"issue":"11","key":"e_1_3_3_6_1","doi-asserted-by":"crossref","first-page":"e202500073","DOI":"10.1002\/tcr.202500073","article-title":"Harnessing chromone as a versatile scaffold for emerging biological applications: recent advances and medicinal insights","volume":"25","author":"Kaishap PP","year":"2025","unstructured":"Kaishap PP, Laskar B, Dutta D, Gogoi N, Dey T. Harnessing chromone as a versatile scaffold for emerging biological applications: recent advances and medicinal insights. Chem Rec. 2025;25(11):e202500073.","journal-title":"Chem Rec"},{"issue":"16","key":"e_1_3_3_7_1","doi-asserted-by":"crossref","first-page":"11096","DOI":"10.1039\/D3RA01383A","article-title":"Anticancer therapeutic potential of benzofuran scaffolds","volume":"13","author":"Abbas AA","year":"2023","unstructured":"Abbas AA, Dawood KM. Anticancer therapeutic potential of benzofuran scaffolds. RSC Adv. 2023;13(16):11096\u201311120.","journal-title":"RSC Adv"},{"issue":"1","key":"e_1_3_3_8_1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11033-026-11976-8","article-title":"Unveiling the anti-cancer properties of apigenin via targeting different molecular signatures: a review","volume":"53","author":"Bhagavatula D","year":"2026","unstructured":"Bhagavatula D, Raina R, Khan U, Vahora H, Dsouza LC, Sinoy T, Banu H, Hussain A. Unveiling the anti-cancer properties of apigenin via targeting different molecular signatures: a review. Mol Biol Rep. 2026;53(1):827.","journal-title":"Mol Biol Rep"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","first-page":"109979","DOI":"10.1016\/j.bioorg.2026.109979","article-title":"Oxazole derivatives as promising kinase inhibitors: a new era in cancer drug discovery","volume":"178","author":"Nath R","year":"2026","unstructured":"Nath R, Debnath B, Maity I, Ashique S, Chakraborty A, Akhtar MJ, Nehra B, Tariq M, Ansari MY, Maity A. Oxazole derivatives as promising kinase inhibitors: a new era in cancer drug discovery. Bioorg Chem. 2026;178:109979.","journal-title":"Bioorg Chem"},{"issue":"7","key":"e_1_3_3_10_1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2174\/1570193X19666211231101747","article-title":"N-heterocycles: recent advances in biological applications","volume":"20","author":"Dinodia M.","year":"2023","unstructured":"Dinodia M. N-heterocycles: recent advances in biological applications. MROC. 2023;20(7):735\u2013747.","journal-title":"MROC"},{"issue":"1","key":"e_1_3_3_11_1","doi-asserted-by":"crossref","DOI":"10.2174\/18741045-v16-e2209010","article-title":"A review on the medicinal and industrial applications of n-containing heterocycles","volume":"16","author":"Amin A","year":"2022","unstructured":"Amin A, Qadir T, Sharma PK, Jeelani I, Abe H. A review on the medicinal and industrial applications of n-containing heterocycles. TOMCJ. 2022;16(1):e187410452209010.","journal-title":"TOMCJ"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","first-page":"122983","DOI":"10.1016\/j.ica.2025.122983","article-title":"Imidazole-based chemosensors: a promising approach for trace copper(II) monitoring","volume":"591","author":"Alam MZ","year":"2026","unstructured":"Alam MZ, Ahmed MS, Parveen H, Mukhtar S, Khan SA. Imidazole-based chemosensors: a promising approach for trace copper(II) monitoring. Inorganica Chim Acta. 2026;591:122983.","journal-title":"Inorganica Chim Acta"},{"issue":"1","key":"e_1_3_3_13_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.55559\/jjbrpac.v3i1.623","article-title":"Facile one-pot synthesis of imidazole (MID): a highly sensitive turn-off fluorescence probe for mercury (II) ion detection","volume":"3","author":"Alam Z","year":"2026","unstructured":"Alam Z, Khan SA. Facile one-pot synthesis of imidazole (MID): a highly sensitive turn-off fluorescence probe for mercury (II) ion detection. Jabirian J Biointerface Res Pharmaceut Appl Chem. 2026;3(1):1\u20137.","journal-title":"Jabirian J Biointerface Res Pharmaceut Appl Chem"},{"issue":"14","key":"e_1_3_3_14_1","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1021\/acs.jmedchem.4c01122","article-title":"An update on the nitrogen heterocycle compositions and properties of U.S. FDA-approved pharmaceuticals (2013\u20132023)","volume":"67","author":"Marshall CM","year":"2024","unstructured":"Marshall CM, Federice JG, Bell CN, Cox PB, Njardarson JT. An update on the nitrogen heterocycle compositions and properties of U.S. FDA-approved pharmaceuticals (2013\u20132023). J Med Chem. 2024;67(14):11622\u201311655.","journal-title":"J Med Chem"},{"issue":"41","key":"e_1_3_3_15_1","doi-asserted-by":"crossref","first-page":"9273","DOI":"10.2174\/0109298673301266240506083014","article-title":"Recent developments in the antimicrobial potential of some nitrogenous heterocycles and their SAR studies: a review","volume":"32","author":"Nehra B","year":"2025","unstructured":"Nehra B, Kumar M, Singh S, Chawla V, Chawla PA, Grover P. Recent developments in the antimicrobial potential of some nitrogenous heterocycles and their SAR studies: a review. Curr Med Chem. 2025;32(41):9273\u20139323.","journal-title":"Curr Med Chem"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","first-page":"117801","DOI":"10.1016\/j.ejmech.2025.117801","article-title":"Recent research frontiers of heterocycles as antifungal agents: insights from the past five years","volume":"295","author":"Tahlan S","year":"2025","unstructured":"Tahlan S, Singh S, Dey H, Kaira M, Pandey KC. Recent research frontiers of heterocycles as antifungal agents: insights from the past five years. Eur J Med Chem. 2025;295:117801.","journal-title":"Eur J Med Chem"},{"issue":"14","key":"e_1_3_3_17_1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.2174\/1568026622666220415224139","article-title":"Recent development of heterocyclic compounds with indazole moiety as potential antiparasitic agents","volume":"22","author":"Paul A","year":"2022","unstructured":"Paul A, Guria T, Roy P, Maity A. Recent development of heterocyclic compounds with indazole moiety as potential antiparasitic agents. Curr Top Med Chem. 2022;22(14):1160\u20131176.","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"e_1_3_3_18_1","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/molecules25040999","article-title":"Allosteric GABAA receptor modulators\u2014a review on the most recent heterocyclic chemotypes and their synthetic accessibility","volume":"25","author":"Vega Alanis BA","year":"2020","unstructured":"Vega Alanis BA, Iorio MT, Silva LL, Bampali K, Ernst M, Schn\u00fcrch M, Mihovilovic MD. Allosteric GABAA receptor modulators\u2014a review on the most recent heterocyclic chemotypes and their synthetic accessibility. Molecules. 2020;25(4):999.","journal-title":"Molecules"},{"issue":"8","key":"e_1_3_3_19_1","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.3390\/ijms27083403","article-title":"The pyrazole scaffold in anticancer drug discovery: a review of synthetic approaches, structure\u2013activity relationships, and target-based mechanism of action","volume":"27","author":"K R K","year":"2026","unstructured":"K R K, Hacholli VB, Gackowski M, Pisklak DM, Kumar A, Szeleszczuk \u0141. The pyrazole scaffold in anticancer drug discovery: a review of synthetic approaches, structure\u2013activity relationships, and target-based mechanism of action. Int J Mol Sci. 2026;27(8):3403.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"e_1_3_3_20_1","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.3390\/molecules27154854","article-title":"Actions of novel angiotensin receptor blocking drugs, bisartans, relevant for COVID-19 therapy: biased agonism at angiotensin receptors and the beneficial effects of neprilysin in the renin angiotensin system","volume":"27","author":"Moore GJ","year":"2022","unstructured":"Moore GJ, Ridgway H, Kelaidonis K, Chasapis CT, Ligielli I, Mavromoustakos T, Bojarska J, Matsoukas JM. Actions of novel angiotensin receptor blocking drugs, bisartans, relevant for COVID-19 therapy: biased agonism at angiotensin receptors and the beneficial effects of neprilysin in the renin angiotensin system. Molecules. 2022;27(15):4854.","journal-title":"Molecules"},{"issue":"5","key":"e_1_3_3_21_1","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1007\/s11030-024-11016-2","article-title":"An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors","volume":"29","author":"Nemr MTM","year":"2025","unstructured":"Nemr MTM, Abdelaziz MA, Teleb M, Elmasry AE, Elshaier YAAM. An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors. Mol Divers. 2025;29(5):4765\u20134785.","journal-title":"Mol Divers"},{"issue":"6","key":"e_1_3_3_22_1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2165\/00003495-200060060-00003","article-title":"Triptans in Migraine","volume":"60","author":"Tfelt-Hansen P","year":"2000","unstructured":"Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in Migraine. Drugs. 2000;60(6):1259\u20131287.","journal-title":"Drugs"},{"issue":"8","key":"e_1_3_3_23_1","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/j.ejmech.2010.04.011","article-title":"Quinolines and structurally related heterocycles as antimalarials","volume":"45","author":"Kaur K","year":"2010","unstructured":"Kaur K, Jain M, Reddy RP, Jain R. Quinolines and structurally related heterocycles as antimalarials. Eur J Med Chem. 2010;45(8):3245\u20133264.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","first-page":"107447","DOI":"10.1016\/j.pharmthera.2019.107447","article-title":"5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future","volume":"206","author":"Vodenkova S","year":"2020","unstructured":"Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther. 2020;206:107447.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"e_1_3_3_25_1","doi-asserted-by":"crossref","first-page":"zcaa002","DOI":"10.1093\/narcan\/zcaa002","article-title":"Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times","volume":"2","author":"Bailly C","year":"2020","unstructured":"Bailly C, Thuru X, Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer. 2020;2(1):zcaa002.","journal-title":"NAR Cancer"},{"issue":"1","key":"e_1_3_3_26_1","doi-asserted-by":"crossref","first-page":"ugag005","DOI":"10.1093\/narmme\/ugag005","article-title":"The fluoropyrimidine polymer CF10 synergizes with 5-ethynyl-2\u2032-deoxyuridine by promoting telomere attrition and mitotic catastrophe","volume":"3","author":"Das U","year":"2026","unstructured":"Das U, Behl A, Gmeiner WH. The fluoropyrimidine polymer CF10 synergizes with 5-ethynyl-2\u2032-deoxyuridine by promoting telomere attrition and mitotic catastrophe. NAR Mol Med. 2026;3(1):ugag005.","journal-title":"NAR Mol Med"},{"issue":"12","key":"e_1_3_3_27_1","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.2174\/0115680266332163241127114029","article-title":"A review on medicinal approaches of novel imatinib derivatives","volume":"25","author":"Kumar S","year":"2025","unstructured":"Kumar S, Agarwal G, Sangwan K. A review on medicinal approaches of novel imatinib derivatives. Curr Top Med Chem. 2025;25(12):1492\u20131516.","journal-title":"Curr Top Med Chem"},{"issue":"7","key":"e_1_3_3_28_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen P","year":"2021","unstructured":"Cohen P, Cross D, J\u00e4nne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20(7):551\u2013569.","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","first-page":"113074","DOI":"10.1016\/j.biopha.2022.113074","article-title":"Application and pharmacological mechanism of methotrexate in rheumatoid arthritis","volume":"150","author":"Zhao Z","year":"2022","unstructured":"Zhao Z, Hua Z, Luo X, Li Y, Yu L, Li M, Lu C, Zhao T, Liu Y. Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomed Pharmacother. 2022;150:113074.","journal-title":"Biomed Pharmacother"},{"issue":"18","key":"e_1_3_3_30_1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJM198311033091805","article-title":"The pharmacology and clinical use of methotrexate","volume":"309","author":"Jolivet J","year":"1983","unstructured":"Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983;309(18):1094\u20131104.","journal-title":"N Engl J Med"},{"issue":"4","key":"e_1_3_3_31_1","first-page":"513","article-title":"Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications","volume":"19","author":"Ortiz R","year":"2021","unstructured":"Ortiz R, Perazzoli G, Cabeza L, Jim\u00e9nez-Luna C, Luque R, Prados J, Melguizo C. Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications. Curr Neuropharmacol. 2021;19(4):513\u2013537.","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"e_1_3_3_32_1","doi-asserted-by":"crossref","first-page":"e70401","DOI":"10.1111\/jcmm.70401","article-title":"Exosomes in the chemoresistance of glioma: key point in chemoresistance","volume":"29","author":"Guo X","year":"2025","unstructured":"Guo X, Piao H, Sui R. Exosomes in the chemoresistance of glioma: key point in chemoresistance. J Cell Mol Med. 2025;29(4):e70401.","journal-title":"J Cell Mol Med"},{"key":"e_1_3_3_33_1","doi-asserted-by":"crossref","first-page":"1700143","DOI":"10.3389\/fchem.2025.1700143","article-title":"Exploring tetrazole chemistry: synthetic techniques, structure\u2013activity relationship, and pharmacological insights in antimicrobial and anticancer therapy","volume":"13","author":"Maji L","year":"2025","unstructured":"Maji L, Teli G, Pal R, Maheshwari N, Soni PK, Matada GSP, Rathore MS, Saravanan V, Muthukumaradoss K. Exploring tetrazole chemistry: synthetic techniques, structure\u2013activity relationship, and pharmacological insights in antimicrobial and anticancer therapy. Front Chem. 2025;13:1700143.","journal-title":"Front Chem"},{"issue":"37","key":"e_1_3_3_34_1","doi-asserted-by":"crossref","first-page":"17221","DOI":"10.1039\/D5SC04490A","article-title":"A new generation of N-heterocyclic carbene (NHC) gold\u2013selenolato complexes as potent anticancer agents: distinct synthetic routes and evaluation in 2D and 3D cancer models","volume":"16","author":"Arnaut P","year":"2025","unstructured":"Arnaut P, Pozsoni NB, Bondar D, Lippmann P, Boschuk S, Semenyuta I, Bhandary S, Van Hecke K, Karpichev Y, Cavarzerani E, et al. A new generation of N-heterocyclic carbene (NHC) gold\u2013selenolato complexes as potent anticancer agents: distinct synthetic routes and evaluation in 2D and 3D cancer models. Chem Sci. 2025;16(37):17221\u201317231.","journal-title":"Chem Sci"},{"issue":"18","key":"e_1_3_3_35_1","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1016\/j.bmc.2019.07.050","article-title":"Synthesis and biological activity of structurally diverse phthalazine derivatives: a systematic review","volume":"27","author":"Sangshetti J","year":"2019","unstructured":"Sangshetti J, Pathan SK, Patil R, Akber Ansari S, Chhajed S, Arote R, Shinde DB. Synthesis and biological activity of structurally diverse phthalazine derivatives: a systematic review. Bioorg Med Chem. 2019;27(18):3979\u20133997.","journal-title":"Bioorg Med Chem"},{"issue":"30","key":"e_1_3_3_36_1","doi-asserted-by":"crossref","first-page":"21668","DOI":"10.1039\/D4RA03459G","article-title":"Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation","volume":"14","author":"Bayoumi HH","year":"2024","unstructured":"Bayoumi HH, Ibrahim M-K, Dahab MA, Khedr F, El-Adl K. Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation. RSC Adv. 2024;14(30):21668\u201321681.","journal-title":"RSC Adv"},{"issue":"4","key":"e_1_3_3_37_1","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1007\/s11030-026-11489-3","article-title":"Phthalazine scaffolds in medicinal chemistry: a review of their synthesis, versatility, and pharmacological significance","volume":"30","author":"Lakkad B","year":"2026","unstructured":"Lakkad B, Hadavani R, Jain V, Jadeja Y. Phthalazine scaffolds in medicinal chemistry: a review of their synthesis, versatility, and pharmacological significance. Mol Divers. 2026;30(4):5017\u20135052.","journal-title":"Mol Divers"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","first-page":"104425","DOI":"10.1016\/j.bioorg.2020.104425","article-title":"Synthetic and medicinal chemistry of phthalazines: recent developments, opportunities and challenges","volume":"105","author":"Zaib S","year":"2020","unstructured":"Zaib S, Khan I. Synthetic and medicinal chemistry of phthalazines: recent developments, opportunities and challenges. Bioorg Chem. 2020;105:104425.","journal-title":"Bioorg Chem"},{"issue":"44","key":"e_1_3_3_39_1","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg S","year":"2008","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AOH, Zander SAL, Derksen PWB, de Bruin M, Zevenhoven J, Lau A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079\u201317084.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"e_1_3_3_40_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong PC","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O\u2019Connor MJ, et al. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u2013134.","journal-title":"N Engl J Med"},{"issue":"8","key":"e_1_3_3_41_1","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann J","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852\u2013861.","journal-title":"Lancet Oncol"},{"issue":"6","key":"e_1_3_3_42_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson M","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u2013533.","journal-title":"N Engl J Med"},{"issue":"26","key":"e_1_3_3_43_1","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore K","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u20132505.","journal-title":"N Engl J Med"},{"issue":"9","key":"e_1_3_3_44_1","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine E","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u20131284.","journal-title":"Lancet Oncol"},{"issue":"12","key":"e_1_3_3_45_1","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.24.00933","article-title":"Olaparib as treatment versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer: phase III SOLO3 study final overall survival results","volume":"43","author":"Scambia G","year":"2025","unstructured":"Scambia G, Villalobos Valencia R, Colombo N, Cibula D, Leath CA, Bidzi\u0144ski M, Kim J-W, Nam JH, Madry R, Hern\u00e1ndez C, et al. Olaparib as treatment versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer: phase III SOLO3 study final overall survival results. J Clin Oncol. 2025;43(12):1408\u20131416.","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_3_3_46_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer","volume":"381","author":"Golan T","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park J-O, Hochhauser D, Arnold D, Oh D-Y, et al. Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u2013327.","journal-title":"N Engl J Med"},{"key":"e_1_3_3_47_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/tbcr-25-11","article-title":"Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies","volume":"6","author":"Abdullah HMA","year":"2025","unstructured":"Abdullah HMA, Chennapragada SS, Singh R, Zeidalkilani JMJ, Kesireddy M. Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies. Transl Breast Cancer Res. 2025;6:24\u201324.","journal-title":"Transl Breast Cancer Res"},{"issue":"18","key":"e_1_3_3_48_1","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen Y","year":"2013","unstructured":"Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A. BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19(18):5003\u20135015.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"e_1_3_3_49_1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers","volume":"7","author":"de Bono J","year":"2017","unstructured":"de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers. Cancer Discov. 2017;7(6):620\u2013629.","journal-title":"Cancer Discov"},{"issue":"9","key":"e_1_3_3_50_1","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-18-1891","article-title":"A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1\/2 mutations (ABRAZO)","volume":"25","author":"Turner NC","year":"2019","unstructured":"Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E-M, Mina LA, Balma\u00f1a J, Fasching PA, Hurvitz SA, et al. A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1\/2 mutations (ABRAZO). Clin Cancer Res. 2019;25(9):2717\u20132724.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"e_1_3_3_51_1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton JK","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee K-H, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753\u2013763.","journal-title":"N Engl J Med"},{"issue":"11","key":"e_1_3_3_52_1","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton JK","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee K-H, Gon\u00e7alves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526\u20131535.","journal-title":"Ann Oncol"},{"issue":"18","key":"e_1_3_3_53_1","doi-asserted-by":"crossref","first-page":"9722","DOI":"10.3390\/ijms22189722","article-title":"Small molecules targeting programmed cell death in breast cancer cells","volume":"22","author":"Maniam S","year":"2021","unstructured":"Maniam S, Maniam S. Small molecules targeting programmed cell death in breast cancer cells. Int J Mol Sci. 2021;22(18):9722.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"e_1_3_3_54_1","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration","volume":"60","author":"Wood JM","year":"2000","unstructured":"Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O\u2019Reilly T, et al. PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60(8):2178\u20132189.","journal-title":"Cancer Res"},{"issue":"12","key":"e_1_3_3_55_1","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1054\/bjoc.2001.2166","article-title":"Effect of VEGF receptor inhibitor PTK787\/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth","volume":"85","author":"Hess C","year":"2001","unstructured":"Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, Glanzmann C, Bodis S, Pruschy M. Effect of VEGF receptor inhibitor PTK787\/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer. 2001;85(12):2010\u20132016.","journal-title":"Br J Cancer"},{"issue":"18","key":"e_1_3_3_56_1","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2005.09.034","article-title":"Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787\/ZK 222584 administered twice daily in patients with advanced cancer","volume":"23","author":"Thomas AL","year":"2005","unstructured":"Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787\/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol. 2005;23(18):4162\u20134171.","journal-title":"J Clin Oncol"},{"issue":"2","key":"e_1_3_3_57_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1593\/neo.91864","article-title":"Phase 1 study of combination treatment with PTK 787\/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis","volume":"12","author":"Langenberg MHG","year":"2010","unstructured":"Langenberg MHG, Witteveen PO, Lankheet NAG, Roodhart JM, Rosing H, van den Heuvel IJGM, Beijnen JH, Voest EE. Phase 1 study of combination treatment with PTK 787\/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis. Neoplasia. 2010;12(2):206\u2013213.","journal-title":"Neoplasia"},{"issue":"11","key":"e_1_3_3_58_1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/bjc.2011.151","article-title":"Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study","volume":"104","author":"Joensuu H","year":"2011","unstructured":"Joensuu H, De Braud F, Grignagni G, De Pas T, Spitalieri G, Coco P, Spreafico C, Boselli S, Toffalorio F, Bono P, et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer. 2011;104(11):1686\u20131690.","journal-title":"Br J Cancer"},{"issue":"3","key":"e_1_3_3_59_1","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/annonc\/mdr255","article-title":"Phase II trial of PTK787\/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB\/IV non-small-cell lung cancer (NSCLC)","volume":"23","author":"Gauler TC","year":"2012","unstructured":"Gauler TC, Besse B, Mauguen A, Meric JB, Gounant V, Fischer B, Overbeck TR, Krissel H, Laurent D, Tiainen M, et al. Phase II trial of PTK787\/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB\/IV non-small-cell lung cancer (NSCLC). Ann Oncol. 2012;23(3):678\u2013687.","journal-title":"Ann Oncol"},{"issue":"5","key":"e_1_3_3_60_1","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10637-013-9978-z","article-title":"A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787\/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)","volume":"31","author":"Gupta P","year":"2013","unstructured":"Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, et al. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787\/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013;31(5):1311\u20131320.","journal-title":"Invest New Drugs"},{"issue":"2","key":"e_1_3_3_61_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-010-0390-7","article-title":"Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide","volume":"103","author":"Gerstner ER","year":"2011","unstructured":"Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011;103(2):325\u2013332.","journal-title":"J Neurooncol"},{"issue":"15","key":"e_1_3_3_62_1","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2010.29.4496","article-title":"Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787\/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma","volume":"29","author":"Hecht JR","year":"2011","unstructured":"Hecht JR, Trarbach T, Hainsworth JD, Major P, J\u00e4ger E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787\/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29(15):1997\u20132003.","journal-title":"J Clin Oncol"},{"issue":"15","key":"e_1_3_3_63_1","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2010.29.5436","article-title":"Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787\/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma","volume":"29","author":"Van Cutsem E","year":"2011","unstructured":"Van Cutsem E, Bajetta E, Valle J, K\u00f6hne C-H, Randolph Hecht J, Moore M, Germond C, Berg W, Chen B-L, Jalava T, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787\/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29(15):2004\u20132010.","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_3_64_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13065-023-00995-2","article-title":"Synthesis of phthalazine-based derivatives as selective anti-breast cancer agents through EGFR-mediated apoptosis: in vitro and in silico studies","volume":"17","author":"Emam SM","year":"2023","unstructured":"Emam SM, Rayes SE, Ali IAI, Soliman HA, Nafie MS. Synthesis of phthalazine-based derivatives as selective anti-breast cancer agents through EGFR-mediated apoptosis: in vitro and in silico studies. BMC Chem. 2023;17(1):90.","journal-title":"BMC Chem"},{"issue":"3","key":"e_1_3_3_65_1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/anie.201610816","article-title":"Discovery of a PCAF bromodomain chemical probe","volume":"56","author":"Moustakim M","year":"2017","unstructured":"Moustakim M, Clark PGK, Trulli L, Fuentes de Arriba AL, Ehebauer MT, Chaikuad A, Murphy EJ, Mendez-Johnson J, Daniels D, Hou CD, et al. Discovery of a PCAF bromodomain chemical probe. Angew Chem Int Ed Engl. 2017;56(3):827\u2013831.","journal-title":"Angew Chem Int Ed Engl"},{"key":"e_1_3_3_66_1","doi-asserted-by":"crossref","first-page":"103899","DOI":"10.1016\/j.bioorg.2020.103899","article-title":"Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies","volume":"100","author":"Abulkhair HS","year":"2020","unstructured":"Abulkhair HS, Turky A, Ghiaty A, Ahmed HEA, Bayoumi AH. Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies. Bioorg Chem. 2020;100:103899.","journal-title":"Bioorg Chem"},{"key":"e_1_3_3_67_1","doi-asserted-by":"crossref","first-page":"104019","DOI":"10.1016\/j.bioorg.2020.104019","article-title":"Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: apoptosis-inductive and PCAF-inhibitory effects","volume":"101","author":"Turky A","year":"2020","unstructured":"Turky A, Bayoumi AH, Ghiaty A, El-Azab AS, A.-M. Abdel-Aziz A, Abulkhair HS. Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: apoptosis-inductive and PCAF-inhibitory effects. Bioorg Chem. 2020;101:104019.","journal-title":"Bioorg Chem"},{"issue":"6","key":"e_1_3_3_68_1","doi-asserted-by":"crossref","first-page":"e2000456","DOI":"10.1002\/ardp.202000456","article-title":"Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors","volume":"354","author":"Sakr H","year":"2021","unstructured":"Sakr H, Ayyad RR, El-Helby AA, Khalifa MM, Mahdy HA. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors. Arch Pharm (Weinheim)). 2021;354(6):e2000456.","journal-title":"Arch Pharm (Weinheim))"},{"issue":"1","key":"e_1_3_3_69_1","doi-asserted-by":"crossref","first-page":"108771","DOI":"10.1016\/j.compbiolchem.2025.108771","article-title":"1,2,4-triazole incorporated into polyheterocyclic scaffolds as anti-glioblastoma agents: biological evaluation and molecular modeling studies","volume":"120","author":"Biega\u0144ski M","year":"2026","unstructured":"Biega\u0144ski M, Bidon M, Karpi\u0144ska M, Rola R, Matysiak J, Niewiadomy A, Szeliga M. 1,2,4-triazole incorporated into polyheterocyclic scaffolds as anti-glioblastoma agents: biological evaluation and molecular modeling studies. Comput Biol Chem. 2026;120(Pt 1):108771.","journal-title":"Comput Biol Chem"},{"issue":"17","key":"e_1_3_3_70_1","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1021\/jm100394y","article-title":"Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor","volume":"53","author":"Cee VJ","year":"2010","unstructured":"Cee VJ, Schenkel LB, Hodous BL, Deak HL, Nguyen HN, Olivieri PR, Romero K, Bak A, Be X, Bellon S, et al. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor. J Med Chem. 2010;53(17):6368\u20136377.","journal-title":"J Med Chem"},{"issue":"11","key":"e_1_3_3_71_1","first-page":"CD004934","article-title":"Hydralazine for essential hypertension","volume":"2011","author":"Kandler MR","year":"2011","unstructured":"Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Hydralazine for essential hypertension. Cochrane Database Syst Rev. 2011;2011(11):CD004934.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"e_1_3_3_72_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1476-5381.1995.tb14931.x","article-title":"Inhibition of calcium release from the sarcoplasmic reticulum of rabbit aorta by hydralazine","volume":"114","author":"Gurney AM","year":"1995","unstructured":"Gurney AM, Allam M. Inhibition of calcium release from the sarcoplasmic reticulum of rabbit aorta by hydralazine. Br J Pharmacol. 1995;114(1):238\u2013244.","journal-title":"Br J Pharmacol"},{"issue":"12","key":"e_1_3_3_73_1","doi-asserted-by":"crossref","first-page":"e1004646","DOI":"10.1371\/journal.pmed.1004646","article-title":"Association of hydralazine use with risk of hematologic neoplasms in patients with hypertension: a nationwide population-based cohort study in Taiwan","volume":"22","author":"Wang L-T","year":"2025","unstructured":"Wang L-T, Chien W-C, Ma KS-K, Chung C-H, Chen Y-C, Tsai W-C, Yang B-H. Association of hydralazine use with risk of hematologic neoplasms in patients with hypertension: a nationwide population-based cohort study in Taiwan. PLoS Med. 2025;22(12):e1004646.","journal-title":"PLoS Med"},{"issue":"1","key":"e_1_3_3_74_1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1186\/s12885-025-14477-2","article-title":"Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells","volume":"25","author":"Yahyapour A","year":"2025","unstructured":"Yahyapour A, Askari N, Yaghoobi MM. Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells. BMC Cancer. 2025;25(1):1427.","journal-title":"BMC Cancer"},{"issue":"1","key":"e_1_3_3_75_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/acs.chemrestox.4c00445","article-title":"Repurposing the antihypertensive agent hydralazine as an inhibitor of the base excision repair enzyme APE1","volume":"38","author":"Islam T","year":"2025","unstructured":"Islam T, Nunna V, Liyanarachchi DP, Melton D, Lewis CD, Gates KS. Repurposing the antihypertensive agent hydralazine as an inhibitor of the base excision repair enzyme APE1. Chem Res Toxicol. 2025;38(1):42\u201345.","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"e_1_3_3_76_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2407-5-44","article-title":"A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes","volume":"5","author":"Zambrano P","year":"2005","unstructured":"Zambrano P, Segura-Pacheco B, Perez-Cardenas E, Cetina L, Revilla-Vazquez A, Taja-Chayeb L, Chavez-Blanco A, Angeles E, Cabrera G, Sandoval K, et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer. 2005;5(1):44.","journal-title":"BMC Cancer"},{"issue":"4","key":"e_1_3_3_77_1","first-page":"354","article-title":"Azelastine nasal spray in the management of seasonal allergic rhinitis","volume":"72","author":"Meltzer EO","year":"1994","unstructured":"Meltzer EO, Weiler JM, Dockhorn RJ, Widlitz MD, Freitag JJ. Azelastine nasal spray in the management of seasonal allergic rhinitis. Ann Allergy. 1994;72(4):354\u2013359.","journal-title":"Ann Allergy"},{"issue":"2","key":"e_1_3_3_78_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1081-1206(10)63420-5","article-title":"Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial","volume":"76","author":"LaForce C","year":"1996","unstructured":"LaForce C, Dockhorn RJ, Prenner BM, Chu TJ, Kraemer MJ, Widlitz MD, D\u2019Eletto TA, Freitag JJ. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol. 1996;76(2):181\u2013188.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"e_1_3_3_79_1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/0091-6749(94)90148-1","article-title":"A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis","volume":"94","author":"Ratner PH","year":"1994","unstructured":"Ratner PH, Findlay SR, Hampel F, van Bavel J, Widlitz MD, Freitag JJ. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol. 1994;94(5):818\u2013825.","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"e_1_3_3_80_1","doi-asserted-by":"crossref","first-page":"11849","DOI":"10.3390\/ijms262411849","article-title":"Azelastine inhibits triple-negative breast cancer cell viability via an ARF1-dependent mechanism","volume":"26","author":"Park SU","year":"2025","unstructured":"Park SU, Jung GU, Paik EK, Lee J-Y, Cho DC, Chung HK, Jo HJ, Jung SJ. Azelastine inhibits triple-negative breast cancer cell viability via an ARF1-dependent mechanism. Int J Mol Sci. 2025;26(24):11849.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"e_1_3_3_81_1","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.3390\/ijms23115890","article-title":"The multidirectional effect of azelastine hydrochloride on cervical cancer cells","volume":"23","author":"Trybus E","year":"2022","unstructured":"Trybus E, Kr\u00f3l T, Trybus W. The multidirectional effect of azelastine hydrochloride on cervical cancer cells. Int J Mol Sci. 2022;23(11):5890.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_3_82_1","doi-asserted-by":"crossref","first-page":"861295","DOI":"10.3389\/fphar.2022.861295","article-title":"The anti-histamine azelastine, identified by computational drug repurposing, inhibits infection by major variants of SARS-CoV-2 in cell cultures and reconstituted human nasal tissue","volume":"13","author":"Konrat R","year":"2022","unstructured":"Konrat R, Papp H, Kimpel J, R\u00f6ssler A, Szij\u00e1rt\u00f3 V, Nagy G, Madai M, Zeghbib S, Kuczmog A, Lanszki Z, et al. The anti-histamine azelastine, identified by computational drug repurposing, inhibits infection by major variants of SARS-CoV-2 in cell cultures and reconstituted human nasal tissue. Front Pharmacol. 2022;13:861295.","journal-title":"Front Pharmacol"},{"key":"e_1_3_3_83_1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.virol.2021.05.009","article-title":"Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2","volume":"560","author":"Ge S","year":"2021","unstructured":"Ge S, Lu J, Hou Y, Lv Y, Wang C, He H. Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2. Virology. 2021;560:110\u2013115.","journal-title":"Virology"},{"issue":"5","key":"e_1_3_3_84_1","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001691","article-title":"Anti-chlamydial effects of azelastine hydrochloride and the impact of the histamine H1 receptor on chlamydial development","volume":"72","author":"Kuratli J","year":"2023","unstructured":"Kuratli J, Leonard CA, Schoborg R, Borel N. Anti-chlamydial effects of azelastine hydrochloride and the impact of the histamine H1 receptor on chlamydial development. J Med Microbiol. 2023;72(5):001691.","journal-title":"J Med Microbiol"},{"issue":"10","key":"e_1_3_3_85_1","first-page":"2463","article-title":"Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the \u03b12\u03b4-1 subunit of voltage gated calcium channel","volume":"14","author":"Lebsack AD","year":"2004","unstructured":"Lebsack AD, Gunzner J, Wang B, Pracitto R, Schaffhauser H, Santini A, Aiyar J, Bezverkov R, Munoz B, Liu W, et al. Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the \u03b12\u03b4-1 subunit of voltage gated calcium channel. Bioorg Med Chem Lett. 2004;14(10):2463\u20132467.","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"e_1_3_3_86_1","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1021\/jm031020p","article-title":"3-Phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity \u03b3-aminobutyric acid-A benzodiazepine receptor ligands with \u03b12, \u03b13, and \u03b15-subtype binding selectivity over \u03b11","volume":"47","author":"Carling RW","year":"2004","unstructured":"Carling RW, Moore KW, Street LJ, Wild D, Isted C, Leeson PD, Thomas S, O\u2019Connor D, McKernan RM, Quirk K, et al. 3-Phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity \u03b3-aminobutyric acid-A benzodiazepine receptor ligands with \u03b12, \u03b13, and \u03b15-subtype binding selectivity over \u03b11. J Med Chem. 2004;47(7):1807\u20131822.","journal-title":"J Med Chem"},{"issue":"9","key":"e_1_3_3_87_1","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2174\/156802611795371350","article-title":"GABAA receptor subtype-selective modulators. I. \u03b12\/\u03b13-selective agonists as non-sedating anxiolytics","volume":"11","author":"R. Atack J.","year":"2011","unstructured":"R. Atack J. GABAA receptor subtype-selective modulators. I. \u03b12\/\u03b13-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176\u20131202.","journal-title":"Curr Top Med Chem"},{"issue":"5","key":"e_1_3_3_88_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1476-5381.2009.00216.x","article-title":"The plasma\u2013occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, \u03b15IA, is similar in rats and primates","volume":"157","author":"Atack JR","year":"2009","unstructured":"Atack JR, Eng W, Gibson RE, Ryan C, Francis B, Sohal B, Dawson GR, Hargreaves RJ, Burns HD. The plasma\u2013occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, \u03b15IA, is similar in rats and primates. Br J Pharmacol. 2009;157(5):796\u2013803.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"e_1_3_3_89_1","doi-asserted-by":"crossref","first-page":"e07895","DOI":"10.1016\/j.heliyon.2021.e07895","article-title":"Prodromal dysfunction of \u03b15GABA-A receptor modulated hippocampal ripples occurs prior to neurodegeneration in the TgF344-AD rat model of Alzheimer\u2019s disease","volume":"7","author":"Ratner MH","year":"2021","unstructured":"Ratner MH, Downing SS, Guo O, Odamah KE, Stewart TM, Kumaresan V, Robitsek RJ, Xia W, Farb DH. Prodromal dysfunction of \u03b15GABA-A receptor modulated hippocampal ripples occurs prior to neurodegeneration in the TgF344-AD rat model of Alzheimer\u2019s disease. Heliyon. 2021;7(9):e07895.","journal-title":"Heliyon"},{"issue":"12","key":"e_1_3_3_90_1","doi-asserted-by":"crossref","DOI":"10.1002\/jmr.2991","article-title":"N-substituted phthalazine sulfonamide derivatives as non-classical aldose reductase inhibitors","volume":"35","author":"T\u00fcrke\u015f C","year":"2022","unstructured":"T\u00fcrke\u015f C, Arslan M, Demir Y, \u00c7o\u00e7aj L, Nixha AR, Beydemir \u015e. N-substituted phthalazine sulfonamide derivatives as non-classical aldose reductase inhibitors. J of Molecular Recognition. 2022;35(12):e2991.","journal-title":"J of Molecular Recognition"},{"key":"e_1_3_3_91_1","doi-asserted-by":"crossref","first-page":"103004","DOI":"10.1016\/j.bioorg.2019.103004","article-title":"Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors","volume":"89","author":"T\u00fcrke\u015f C","year":"2019","unstructured":"T\u00fcrke\u015f C, Arslan M, Demir Y, \u00c7o\u00e7aj L, Rifati Nixha A, Beydemir \u015e. Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors. Bioorg Chem. 2019;89:103004.","journal-title":"Bioorg Chem"},{"issue":"13","key":"e_1_3_3_92_1","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1021\/ol301167q","article-title":"One-pot synthesis of phthalazines and pyridazino-aromatics: a novel strategy for substituted naphthalenes","volume":"14","author":"Kessler SN","year":"2012","unstructured":"Kessler SN, Wegner HA. One-pot synthesis of phthalazines and pyridazino-aromatics: a novel strategy for substituted naphthalenes. Org Lett. 2012;14(13):3268\u20133271.","journal-title":"Org Lett"},{"key":"e_1_3_3_93_1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2018.10.047","article-title":"Recent advances in the synthesis of phthalazin-1(2H)-one core as a relevant pharmacophore in medicinal chemistry","volume":"161","author":"Ter\u00e1n C","year":"2019","unstructured":"Ter\u00e1n C, Besada P, Vila N, Costas-Lago MC. Recent advances in the synthesis of phthalazin-1(2H)-one core as a relevant pharmacophore in medicinal chemistry. Eur J Med Chem. 2019;161:468\u2013478.","journal-title":"Eur J Med Chem"},{"issue":"15","key":"e_1_3_3_94_1","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1016\/j.bmcl.2006.04.087","article-title":"Anti-HIV activity of stilbene-related heterocyclic compounds","volume":"16","author":"Bedoya LM","year":"2006","unstructured":"Bedoya LM, del Olmo E, Sancho R, Barboza B, Beltr\u00e1n M, Garc\u00eda-Cadenas AE, S\u00e1nchez-Palomino S, L\u00f3pez-P\u00e9rez JL, Mu\u00f1oz E, Feliciano AS, et al. Anti-HIV activity of stilbene-related heterocyclic compounds. Bioorg Med Chem Lett. 2006;16(15):4075\u20134079.","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_3_95_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/jpri\/2019\/v27i630189","article-title":"An overview of different synthetic routes for the synthesis of phthalazine derivatives","author":"Singh S","year":"2019","unstructured":"Singh S, Kumar N. An overview of different synthetic routes for the synthesis of phthalazine derivatives. JPRI. 2019;27(6):1\u201315.","journal-title":"JPRI"},{"issue":"1","key":"e_1_3_3_96_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0960-894X(00)00587-4","article-title":"Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives","volume":"11","author":"Napoletano M","year":"2001","unstructured":"Napoletano M, Norcini G, Pellacini F, Marchini F, Morazzoni G, Ferlenga P, Pradella L. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives. Bioorg Med Chem Lett. 2001;11(1):33\u201337.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"e_1_3_3_97_1","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1038\/s41598-025-87258-3","article-title":"Rational design, synthesis, in vitro, and in-silico studies of pyrazole-phthalazine hybrids as new \u03b1-glucosidase inhibitors","volume":"15","author":"Roshan M","year":"2025","unstructured":"Roshan M, Mirzazadeh R, Tajmir-Riahi A, Asgari MS. Rational design, synthesis, in vitro, and in-silico studies of pyrazole-phthalazine hybrids as new \u03b1-glucosidase inhibitors. Sci Rep. 2025;15(1):3744.","journal-title":"Sci Rep"},{"issue":"1","key":"e_1_3_3_98_1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/14756366.2019.1642883","article-title":"Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition","volume":"34","author":"Elmeligie S","year":"2019","unstructured":"Elmeligie S, Aboul-Magd AM, Lasheen DS, Ibrahim TM, Abdelghany TM, Khojah SM, Abouzid KAM. Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition. J Enzyme Inhib Med Chem. 2019;34(1):1347\u20131367.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"8","key":"e_1_3_3_99_1","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1016\/j.ejmech.2010.05.016","article-title":"Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives","volume":"45","author":"Zhang S","year":"2010","unstructured":"Zhang S, Zhao Y, Liu Y, Chen D, Lan W, Zhao Q, Dong C, Xia L, Gong P. Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives. Eur J Med Chem. 2010;45(8):3504\u20133510.","journal-title":"Eur J Med Chem"},{"issue":"15","key":"e_1_3_3_100_1","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/S0040-4020(01)91312-2","article-title":"New convenient one-step synthesis of 4-arylphthalaz-1 -ones","volume":"40","author":"Fekry Ismail M","year":"1984","unstructured":"Fekry Ismail M, El-Bassiouny FA, Younes HA. New convenient one-step synthesis of 4-arylphthalaz-1 -ones. Tetrahedron. 1984;40(15):2983\u20132984.","journal-title":"Tetrahedron"},{"issue":"02","key":"e_1_3_3_101_1","doi-asserted-by":"crossref","first-page":"0221","DOI":"10.1055\/s-2001-10804","article-title":"A new and convenient synthesis of 3-Aryl-3-hydroxyisoindol-1-ones and their aza analogs","volume":"2001","author":"Saito Y","year":"2001","unstructured":"Saito Y, Sakamoto T, Kikugawa Y. A new and convenient synthesis of 3-Aryl-3-hydroxyisoindol-1-ones and their aza analogs. Synthesis (Stuttg). 2001;2001(02):0221\u20130224.","journal-title":"Synthesis (Stuttg)"},{"issue":"8","key":"e_1_3_3_102_1","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1021\/jo3000628","article-title":"Synthesis of 4-substituted chlorophthalazines, dihydrobenzoazepinediones, 2-pyrazolylbenzoic acid, and 2-pyrazolylbenzohydrazide via 3-substituted 3-hydroxyisoindolin-1-ones","volume":"77","author":"Nguyen HN","year":"2012","unstructured":"Nguyen HN, Cee VJ, Deak HL, Du B, Faber KP, Gunaydin H, Hodous BL, Hollis SL, Krolikowski PH, Olivieri PR, et al. Synthesis of 4-substituted chlorophthalazines, dihydrobenzoazepinediones, 2-pyrazolylbenzoic acid, and 2-pyrazolylbenzohydrazide via 3-substituted 3-hydroxyisoindolin-1-ones. J Org Chem. 2012;77(8):3887\u20133906.","journal-title":"J Org Chem"},{"issue":"7","key":"e_1_3_3_103_1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.tetlet.2003.12.070","article-title":"Synthesis of benzo[4,5]imidazo[2,1- a] phthalazines","volume":"45","author":"Shubin KM","year":"2004","unstructured":"Shubin KM, Kuznetsov VA, Galishev VA. Synthesis of benzo[4,5]imidazo[2,1- a] phthalazines. Tetrahedron Lett. 2004;45(7):1407\u20131408.","journal-title":"Tetrahedron Lett"},{"issue":"5","key":"e_1_3_3_104_1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1134\/S1070428008050175","article-title":"Benzo[4,5]imidazo[2,1-a]phthalazines: I. substituted o-nitrophenylhydrazines in the synthesis of phthalazin-1(2H)-ones","volume":"44","author":"Kuznetsov VA","year":"2008","unstructured":"Kuznetsov VA, Shubin KM, Shchipalkin AA, Teplyakov FS, Petrov ML. Benzo[4,5]imidazo[2,1-a]phthalazines: I. substituted o-nitrophenylhydrazines in the synthesis of phthalazin-1(2H)-ones. Russ J Org Chem. 2008;44(5):731\u2013735.","journal-title":"Russ J Org Chem"},{"issue":"1","key":"e_1_3_3_105_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1747519819883840","article-title":"Phthalazines and phthalazine hybrids as antimicrobial agents: synthesis and biological evaluation","volume":"44","author":"Mourad AK","year":"2020","unstructured":"Mourad AK, Makhlouf AA, Soliman AY, Mohamed SA. Phthalazines and phthalazine hybrids as antimicrobial agents: synthesis and biological evaluation. J Chem Res. 2020;44(1-2):31\u201341.","journal-title":"J Chem Res"},{"issue":"26","key":"e_1_3_3_106_1","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/jo702000d","article-title":"Iptycene-derived pyridazines and phthalazines","volume":"72","author":"Bouffard J","year":"2007","unstructured":"Bouffard J, Eaton RF, M\u00fcller P, Swager TM. Iptycene-derived pyridazines and phthalazines. J Org Chem. 2007;72(26):10166\u201310180.","journal-title":"J Org Chem"},{"issue":"37","key":"e_1_3_3_107_1","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1016\/S0040-4039(01)01302-8","article-title":"A convenient access to benzo-substituted phthalazines as potential precursors to DNA intercalators","volume":"42","author":"Tsoungas PG","year":"2001","unstructured":"Tsoungas PG, Searcey M. A convenient access to benzo-substituted phthalazines as potential precursors to DNA intercalators. Tetrahedron Lett. 2001;42(37):6589\u20136592.","journal-title":"Tetrahedron Lett"},{"issue":"4","key":"e_1_3_3_108_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0040-4039(81)80093-7","article-title":"Phthalazine derivatives from aromatic aldazines","volume":"22","author":"Robev SK.","year":"1981","unstructured":"Robev SK. Phthalazine derivatives from aromatic aldazines. Tetrahedron Lett. 1981;22(4):345\u2013348.","journal-title":"Tetrahedron Lett"},{"issue":"9","key":"e_1_3_3_109_1","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1039\/C5SC01726B","article-title":"Triple aryne-tetrazine reaction enabling rapid access to a new class of polyaromatic heterocycles","volume":"6","author":"Suh S-E","year":"2015","unstructured":"Suh S-E, Barros SA, Chenoweth DM. Triple aryne-tetrazine reaction enabling rapid access to a new class of polyaromatic heterocycles. Chem Sci. 2015;6(9):5128\u20135132.","journal-title":"Chem Sci"},{"issue":"39","key":"e_1_3_3_110_1","doi-asserted-by":"crossref","first-page":"7688","DOI":"10.1039\/C8SC01796D","article-title":"The mechanism of the triple aryne\u2013tetrazine reaction cascade: theory and experiment","volume":"9","author":"Suh S-E","year":"2018","unstructured":"Suh S-E, Chen S, Houk KN, Chenoweth DM. The mechanism of the triple aryne\u2013tetrazine reaction cascade: theory and experiment. Chem Sci. 2018;9(39):7688\u20137693.","journal-title":"Chem Sci"},{"issue":"6","key":"e_1_3_3_111_1","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.tet.2004.11.071","article-title":"Synthesis of the possible carcinogenic dihydrodiol and diol epoxide of phthalazine","volume":"61","author":"\u00d6zer G","year":"2005","unstructured":"\u00d6zer G, Saracoglu N, Menzek A, Balci M. Synthesis of the possible carcinogenic dihydrodiol and diol epoxide of phthalazine. Tetrahedron. 2005;61(6):1545\u20131550.","journal-title":"Tetrahedron"},{"issue":"10","key":"e_1_3_3_112_1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/slct.202204329","article-title":"Synthesis of some new phthalazine\u2009\u2212\u2009piperazine\u2009\u2212\u2009pyrazole conjugates; in vitro anti-cancer, ADMET and molecular docking studies","volume":"8","author":"Badithapuram V","year":"2023","unstructured":"Badithapuram V, Kumar Nukala S, Dasari G, Swamy Thirukovela N, Bandari S. Synthesis of some new phthalazine\u2009\u2212\u2009piperazine\u2009\u2212\u2009pyrazole conjugates; in vitro anti-cancer, ADMET and molecular docking studies. ChemistrySelect. 2023;8(10):565\u2013575.","journal-title":"ChemistrySelect"},{"key":"e_1_3_3_113_1","doi-asserted-by":"crossref","first-page":"1469677","DOI":"10.3389\/fchem.2024.1469677","article-title":"Highlighting multicomponent reactions as an efficient and facile alternative route in the chemical synthesis of organic-based molecules: a tremendous growth in the past 5 years","volume":"12","author":"Mohlala RL","year":"2024","unstructured":"Mohlala RL, Rashamuse TJ, Coyanis EM. Highlighting multicomponent reactions as an efficient and facile alternative route in the chemical synthesis of organic-based molecules: a tremendous growth in the past 5 years. Front Chem. 2024;12:1469677.","journal-title":"Front Chem"},{"issue":"4","key":"e_1_3_3_114_1","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1007\/s11030-026-11469-7","article-title":"Multicomponent reactions with Meldrum\u2019s acid and isocyanides as a valuable synthetic approach: an update","volume":"30","author":"Ardeshiri HH","year":"2026","unstructured":"Ardeshiri HH, Tirabadi GG, Shaabani A. Multicomponent reactions with Meldrum\u2019s acid and isocyanides as a valuable synthetic approach: an update. Mol Divers. 2026;30(4):5175\u20135190.","journal-title":"Mol Divers"},{"issue":"19","key":"e_1_3_3_115_1","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/ejoc.201800159","article-title":"Palladium-catalyzed acylation reactions: a one-pot diversified synthesis of phthalazines, phthalazinones and benzoxazinones","volume":"2018","author":"Suchand B","year":"2018","unstructured":"Suchand B, Satyanarayana G. Palladium-catalyzed acylation reactions: a one-pot diversified synthesis of phthalazines, phthalazinones and benzoxazinones. Eur J Org Chem. 2018;2018(19):2233\u20132246.","journal-title":"Eur J Org Chem"},{"issue":"20","key":"e_1_3_3_116_1","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1021\/ol502498y","article-title":"Palladium-catalyzed phthalazinone synthesis using paraformaldehyde as carbon source","volume":"16","author":"Wang H","year":"2014","unstructured":"Wang H, Cai J, Huang H, Deng G-J. Palladium-catalyzed phthalazinone synthesis using paraformaldehyde as carbon source. Org Lett. 2014;16(20):5324\u20135327.","journal-title":"Org Lett"},{"issue":"28","key":"e_1_3_3_117_1","doi-asserted-by":"crossref","first-page":"8596","DOI":"10.1002\/chem.201200267","article-title":"Palladium-catalyzed synthesis of phthalazinones: efficient carbonylative coupling of 2-bromobenzaldehydes and hydrazines","volume":"18","author":"Wu X","year":"2012","unstructured":"Wu X, Neumann H, Neumann S, Beller M. Palladium-catalyzed synthesis of phthalazinones: efficient carbonylative coupling of 2-bromobenzaldehydes and hydrazines. Chemistry. 2012;18(28):8596\u20138599.","journal-title":"Chemistry"},{"issue":"47","key":"e_1_3_3_118_1","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1016\/j.tet.2011.09.095","article-title":"Synthesis of tetrahydrophthalazine and phthalamide (phthalimide) derivatives via palladium-catalysed carbonylation of iodoarenes","volume":"67","author":"Marosv\u00f6lgyi-Hask\u00f3 D","year":"2011","unstructured":"Marosv\u00f6lgyi-Hask\u00f3 D, Petz A, Tak\u00e1cs A, Koll\u00e1r L. Synthesis of tetrahydrophthalazine and phthalamide (phthalimide) derivatives via palladium-catalysed carbonylation of iodoarenes. Tetrahedron. 2011;67(47):9122\u20139128.","journal-title":"Tetrahedron"},{"issue":"28","key":"e_1_3_3_119_1","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1016\/j.tetlet.2013.05.006","article-title":"Microwave assisted palladium-catalyzed synthesis of phthalazinones and pyridopyridazinones","volume":"54","author":"Rao KP","year":"2013","unstructured":"Rao KP, Basak AK, Deb PK, Sharma S, Reddy LK. Microwave assisted palladium-catalyzed synthesis of phthalazinones and pyridopyridazinones. Tetrahedron Lett. 2013;54(28):3694\u20133696.","journal-title":"Tetrahedron Lett"},{"issue":"13","key":"e_1_3_3_120_1","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1021\/jo401131p","article-title":"Multicomponent synthesis of 4-aminophthalazin-1(2H)-ones by palladium-catalyzed isocyanide insertion","volume":"78","author":"Vlaar T","year":"2013","unstructured":"Vlaar T, Mampuys P, Helliwell M, Maes BUW, Orru RVA, Ruijter E. Multicomponent synthesis of 4-aminophthalazin-1(2H)-ones by palladium-catalyzed isocyanide insertion. J Org Chem. 2013;78(13):6735\u20136745.","journal-title":"J Org Chem"},{"issue":"24","key":"e_1_3_3_121_1","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1021\/ol202784d","article-title":"Palladium-catalyzed synthesis of 4-aminophthalazin-1(2H)-ones by isocyanide insertion","volume":"13","author":"Vlaar T","year":"2011","unstructured":"Vlaar T, Ruijter E, Znabet A, Janssen E, de Kanter FJJ, Maes BUW, Orru RVA. Palladium-catalyzed synthesis of 4-aminophthalazin-1(2H)-ones by isocyanide insertion. Org Lett. 2011;13(24):6496\u20136499.","journal-title":"Org Lett"},{"issue":"1","key":"e_1_3_3_122_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1021\/jo3022956","article-title":"Reaction of 1-nitroso-2-naphthols with \u03b1-functionalized ketones and related compounds: the unexpected formation of decarbonylated 2-substituted naphtho[1,2-d][1,3]oxazoles","volume":"78","author":"Aljaar N","year":"2013","unstructured":"Aljaar N, Malakar CC, Conrad J, Frey W, Beifuss U. Reaction of 1-nitroso-2-naphthols with \u03b1-functionalized ketones and related compounds: the unexpected formation of decarbonylated 2-substituted naphtho[1,2-d][1,3]oxazoles. J Org Chem. 2013;78(1):154\u2013166.","journal-title":"J Org Chem"},{"issue":"8","key":"e_1_3_3_123_1","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1039\/C6SC01095D","article-title":"Visible light amination\/smiles cascade: access to phthalazine derivatives","volume":"7","author":"Brachet E","year":"2016","unstructured":"Brachet E, Marzo L, Selkti M, K\u00f6nig B, Belmont P. Visible light amination\/smiles cascade: access to phthalazine derivatives. Chem Sci. 2016;7(8):5002\u20135006.","journal-title":"Chem Sci"},{"issue":"9","key":"e_1_3_3_124_1","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1007\/s11164-025-05682-6","article-title":"A convenient metal-free one-pot synthesis of some phthalazine derivatives mediated by 3-picolinic acid","volume":"51","author":"Islam I","year":"2025","unstructured":"Islam I, Hossain A, Das SR, Mominuddin M, Roy PK, Karmaker PG, Roy HN. A convenient metal-free one-pot synthesis of some phthalazine derivatives mediated by 3-picolinic acid. Res Chem Intermed. 2025;51(9):4985\u20134997.","journal-title":"Res Chem Intermed"},{"key":"e_1_3_3_125_1","doi-asserted-by":"crossref","first-page":"105740","DOI":"10.1016\/j.bioorg.2022.105740","article-title":"Controlled microwave-assisted reactions: a facile synthesis of polyfunctionally substituted phthalazines as dual EGFR and PI3K inhibitors in CNS SNB-75 cell line","volume":"122","author":"Hassan Nazmy M","year":"2022","unstructured":"Hassan Nazmy M, Ahmed Mekheimer R, Shoman ME, Abo-Elsebaa M, Abd-Elmonem M, Usef Sadek K. Controlled microwave-assisted reactions: a facile synthesis of polyfunctionally substituted phthalazines as dual EGFR and PI3K inhibitors in CNS SNB-75 cell line. Bioorg Chem. 2022;122:105740.","journal-title":"Bioorg Chem"},{"issue":"1","key":"e_1_3_3_126_1","doi-asserted-by":"crossref","first-page":"14275","DOI":"10.1038\/s41598-026-47154-w","article-title":"Novel green synthesis of polyfunctionally substituted phthalazines promoted by visible light, DFT studies and molecular docking with antimicrobial and antibiofilm potency","volume":"16","author":"Mekheimer RA","year":"2026","unstructured":"Mekheimer RA, Khalifa BA, Hashem ZS, Allam SMR, Sadek KU, Eletmany MR. Novel green synthesis of polyfunctionally substituted phthalazines promoted by visible light, DFT studies and molecular docking with antimicrobial and antibiofilm potency. Sci Rep. 2026;16(1):14275.","journal-title":"Sci Rep"},{"issue":"36","key":"e_1_3_3_127_1","doi-asserted-by":"crossref","first-page":"38262","DOI":"10.1021\/acsomega.4c05587","article-title":"Green one-pot synthesis of thiazole scaffolds catalyzed by reusable NiFe 2 O 4 nanoparticles: In silico binding affinity and in vitro anticancer activity studies","volume":"9","author":"Gudala S","year":"2024","unstructured":"Gudala S, Sharma A, Lankada A, Liu R, Jha A, Penta S, Dar OI, Yang J. Green one-pot synthesis of thiazole scaffolds catalyzed by reusable NiFe 2 O 4 nanoparticles: In silico binding affinity and in vitro anticancer activity studies. ACS Omega. 2024;9(36):38262\u201338271.","journal-title":"ACS Omega"},{"issue":"4","key":"e_1_3_3_128_1","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/jhet.649","article-title":"An efficient one-pot synthesis of pyridazinones and phthalazinones using HY-zeolite","volume":"48","author":"Zare L","year":"2011","unstructured":"Zare L, Mahmoodi N, Yahyazadeh A, Mamaghani M, Tabatabaeian K. An efficient one-pot synthesis of pyridazinones and phthalazinones using HY-zeolite. Journal of Heterocyclic Chem. 2011;48(4):864\u2013867.","journal-title":"Journal of Heterocyclic Chem"},{"key":"e_1_3_3_129_1","doi-asserted-by":"crossref","first-page":"123997","DOI":"10.1016\/j.jorganchem.2025.123997","article-title":"Design and synthesis of novel phthalazine and benzofuran scaffolds using CoFe2O4@CNSCu nanocatalyst: evaluation of PARP-1 inhibitory activity","volume":"1047","author":"Moghaddam FM","year":"2026","unstructured":"Moghaddam FM, Fazli H, Sadredini S. Design and synthesis of novel phthalazine and benzofuran scaffolds using CoFe2O4@CNSCu nanocatalyst: evaluation of PARP-1 inhibitory activity. J Organomet Chem. 2026;1047:123997.","journal-title":"J Organomet Chem"}],"container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2717060","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14756366.2026.2717060","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2717060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:08:27Z","timestamp":1789718907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14756366.2026.2717060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14756366.2026.2717060"],"URL":"https:\/\/doi.org\/10.1080\/14756366.2026.2717060","relation":{},"ISSN":["1475-6366","1475-6374"],"issn-type":[{"value":"1475-6366","type":"print"},{"value":"1475-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2717060"}}